ACIXF (Acarix AB) Ending Cash Position: $2.77 Mil (As of Mar. 2026)


ACIXF Acarix AB ACIXF
44 GF Score
Price $0.03
GF Value $0.02
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Acarix AB Ending Cash Position?

Acarix AB ACIXF 44 Ending Cash Position is $2.77 Mil as of Mar. 2026. GuruFocus rates ACIXF with a GF Score™ of 44/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Acarix AB's Ending Cash Position for the quarter that ended in Mar. 2026 was $2.77 Mil.

Acarix AB's quarterly Ending Cash Position declined from Sep. 2025 ($2.60 Mil) to Dec. 2025 ($1.97 Mil) but then increased from Dec. 2025 ($1.97 Mil) to Mar. 2026 ($2.77 Mil).

Acarix AB's annual Ending Cash Position increased from Dec. 2023 ($3.43 Mil) to Dec. 2024 ($5.34 Mil) but then declined from Dec. 2024 ($5.34 Mil) to Dec. 2025 ($1.97 Mil).

Acarix AB Ending Cash Position Related Terms

Acarix AB Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Acarix AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acarix AB Ending Cash Position Chart

Acarix AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.75 1.08 3.43 5.34 1.97

Acarix AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.45 3.38 2.60 1.97 2.77
ACIXF
44GF Score
Acarix AB ACIXF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acarix AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Acarix AB's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=6.306+-4.34
=1.97

Acarix AB's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.961+0.807
=2.77

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2.77 Mil mean?
Acarix AB (ACIXF) has a Ending Cash Position of $2.77 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Acarix AB and its competitors.
Is Acarix AB's Ending Cash Position too high?
Acarix AB's current Ending Cash Position is $2.77 Mil. Overall, Acarix AB has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's Ending Cash Position compare to ABT and SYK?
Acarix AB's Ending Cash Position of $2.77 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Devices & Instruments company?
A good Ending Cash Position depends on the Medical Devices & Instruments industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Acarix AB and its competitors. Acarix AB's current Ending Cash Position is $2.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Based on GuruFocus' analysis, Acarix AB (ACIXF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $0.03 — trading 39.3% above its estimated fair value. The current Ending Cash Position is $2.77 Mil. Acarix AB's overall GF Score™ is 44/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Acarix AB (ACIXF), the current Ending Cash Position is $2.77 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Acarix AB (ACIXF) Overvalued in 2026?

Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued. The current stock price of $0.03 is trading 39.3% above its estimated GF Value™ of $0.02. GuruFocus considers Acarix AB to be Significantly Overvalued.

Key valuation signals for ACIXF:

  • Ending Cash Position: $2.77 Mil
  • GF Value™: $0.02 vs. price of $0.03 (39.3% above fair value)
  • GF Score™: 44/100 with 1 warning sign

No single metric tells the full story. See the ACIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Acarix AB Business Description

Other Exchanges ACARIX:Sweden
Address Hyllie Boulevard 34, Regus Malmo, Malmo, SWE, 215 32
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
44GF Score

Get the complete analysis for ACIXF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price
$0.02
GF Value